title: M_95A_2672_CB_0_GS

description:
Site: University of Michigan
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.98
Subject: 2672
Gender: Female
Chip: Affymetrix GeneChip Human Genome U95A
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: M_95A_2822_CB_1_GS

status: Public on Jan 28 2005

type: RNA

city: Irvine

first: Marquis

last: Vawter

state: CA

address: Gillespie Neuroscience, Room 2119

department: Psychiatry and Human Behavior

country: USA

institute: University of California, Irvine

description:
Site: University of Michigan
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.86
Subject: 2822
Gender: Male
Chip: Affymetrix GeneChip Human Genome U95A
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.

molecule: total RNA

organism: Homo sapiens

source_name: Brain region: CB (cerebellum)


title: I_95Av2_2672_CB_0_GS

description:
Site: University of California, Irvine
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.98
Subject: 2672
Gender: Female
Chip: Affymetrix GeneChip Human Genome U95A Version 2
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: M_95A_2672_DLPFC_0_GS

source_name: Brain region: DLPFC (dorsolateral prefrontal cortex)


title: D_95Av2_2822_CB_1_GS

description:
Site: University of California, Davis
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.86
Subject: 2822
Gender: Male
Chip: Affymetrix GeneChip Human Genome U95A Version 2
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: M_95A_2822_DLPFC_1_GS


title: M_95A_1905_DLPFC_1_GS

description:
Site: University of Michigan
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.94
Subject: 1905
Gender: Male
Chip: Affymetrix GeneChip Human Genome U95A
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: M_95A_1905_Cg_1_GS

source_name: Brain region: AnCg (anterior cingulate cortex)


title: D_95A_1871_CB_0_GS

description:
Site: University of California, Davis
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.13
Subject: 1871
Gender: Female
Chip: Affymetrix GeneChip Human Genome U95A
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: M_95A_2672_Cg_0_GS


title: D_95A_2672_CB_0_GS

description:
Site: University of California, Davis
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.98
Subject: 2672
Gender: Female
Chip: Affymetrix GeneChip Human Genome U95A
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: I_95Av2_2672_DLPFC_0_GS_B


title: M_95A_1905_CB_1_GS


title: I_95Av2_1871_DLPFC_0_GS

description:
Site: University of California, Irvine
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.13
Subject: 1871
Gender: Female
Chip: Affymetrix GeneChip Human Genome U95A Version 2
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: D_95Av2_2672_DLPFC_0_GS

description:
Site: University of California, Davis
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.98
Subject: 2672
Gender: Female
Chip: Affymetrix GeneChip Human Genome U95A Version 2
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: I_95Av2_2672_DLPFC_0_GS


title: D_95Av2_1905_DLPFC_1_GS

description:
Site: University of California, Davis
Diagnosis: Control
pH: 6.94
Subject: 1905
Gender: Male
Chip: Affymetrix GeneChip Human Genome U95A Version 2
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: I_95Av2_1905_Cg_1_GS

description:
Site: University of California, Irvine
Cohort: Male/Female Control Set
Diagnosis: Control
pH: 6.94
Subject: 1905
Gender: Male
Chip: Affymetrix GeneChip Human Genome U95A Version 2
We appreciate the assistance of Richard Stein, Ph.D. and Preston Cartagena, Psy.D. for their contributions to postmortem clinical characterization of subjects.  We acknowledge Kathleen Burke as well as Jacque Berndt and the investigators and medical examiners at the Orange County Coroners Office for procurement of brain tissue.  We also appreciate the technical contributions of Kevin Overman, Sharon Burke, and Phong Nguyen.  F. Warren Lovell, M.D, performed a neuropathological evaluation of the postmortem brains.  Tissue specimens were processed and stored at the Human Brain and Spinal Fluid Resource Center, Veteran's Medical Center, Los Angeles under the direction of Wallace W. Tourtellotte, M.D., Ph.D.  This project is supported by the NIMH Conte Center Grant P50 MH60398, Pritzker Neuropsychiatric Disorders Research Consortium, William Lion Penzner Foundation (UCI), Della Martin Foundation (UCI), NIMH Grant #MH54844 (EGJ), W.M. Keck Foundation (EGJ), and the NIMH Program Project MH42251 (SJW and HA).  The authors are members of of a Conte Center supported by the NIMH and the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, the University of California, and Stanford University to encourage the development of appropriate findings for research and clinical applications.


title: I_95Av2_1905_DLPFC_1_GS_B


title: X285e

status: Public on Jan 18 2005

city: Basel

first: Florent

last: Baty

address: Petersgraben 4

department: Pneumology

country: Switzerland

institute: Universitätsspital Basel

description:
Follow up 6 month after; Sarcoidosis stage II/III;Active;Age=-;Sex=-
Keywords = DNA Microarrays, sarcoidosis, inflammation, follow-up study

source_name: peripheral blood cell


title: I_95Av2_1905_DLPFC_1_GS


title: X286e

description:
Follow up 6 month after; Sarcoidosis stage I;Remission;Age=-;Sex=-
Keywords = DNA Microarrays, sarcoidosis, inflammation, follow-up study


title: X289e


title: X290e


title: X284e


title: I_95Av2_1905_CB_1_GS


title: LacZ, #2 repeat

status: Public on Jan 01 2005

city: Louisville

first: Kelly

middle: M

last: McMasters

state: KY

address: 580 South Preston, Room# 326

department: Surgery

institute: University Of Louisville

description:
E2F-1 gene expression profiling by adenovirus-mediated gene transfer in SKMEL-2 melanoma cell line.
Keywords = E2F-1
Keywords = apoptosis
Keywords = adenovirus
Keywords = cell cycle
Keywords = ASK-1
Keywords = microarray
Keywords = melanoma
Keywords = gene therapy

source_name: SK-MEL-2 Melanoma cell line


title: E2F-1, #2 repeat

source_name: SK-MEL-2 melanoma cell line


title: LacZ, #1 repeat

source_name: SK-MEL-2 melanoma cells


title: X287e


title: Male twin pair 2 (M4)

status: Public on Dec 31 2004

city: Delhi

first: Srinivasan

last: Ramachandran

email: ramu@igib.res.in, ramucbt@yahoo.com

state: Delhi

address: Mall Road (Near Delhi University Campu)

department: Functional Genomics Unit

country: India

institute: Institute of Genomics and Integrative Biology

description: Blood was collected in ACD containing vacutainers. RBCs were lysed using lysis buffer, and WBCs were subsequently pelleted. Total RNA was extracted from this sample using EZ-RNA isolation kit (Biological Industries, Israel). Targets were produced using standard Affymetrix procedures from 8 microgram of total RNA.

source_name: whole blood


title: Male twin pair 2 (M5)


title: Female twin pair 2 (F5)


title: X282e


title: Female Twin Pair 3 (F7)


title: Female Twin Pair 2 (F6)

description:
Blood was collected in ACD containing vacutainers. RBCs were lysed using lysis
buffer, and WBCs were subsequently pelleted. Total RNA was extracted from this
sample using EZ-RNA isolation kit (Biological Industries, Israel). Targets were
produced using standard Affymetrix procedures from 8 microgram of total RNA.


title: Female Twin Pair 1 (F1)


title: Female Twin Pair 1 (F2)


title: Female twin pair 3 (F8)


title: Unrelated Male (M3) different time point


title: E2F-1, #1 repeat


title: Male Twin Pair 1 (M2)


title: Unrelated Male (M3) replicate


title: X283e


title: Male twin pair 1 (M1)


title: U87 parent chip 3

status: Public on Dec 10 2004

city: Lexington

first: David

middle: Murray

last: Kaetzel

address: 800 Rose Street

department: Molecular and Biomedical Pharmacology

institute: University of Kentucky College of Medicine

description:
U87 glioblastoma cell, parent
Keywords = bioinformatics
Keywords = gene expression
Keywords = cancer
Keywords = platelet-derived growth factor
Keywords = sterol regulatory element binding protein
Keywords = glioblastoma multiformae
Keywords = microarray

source_name: U87 glioblastoma, parent


title: U87 parent chip 2


title: U87 parent chip 1


title: Clone 8.1 plus PDGF chip 1

description:
U87 glioblastoma cell, clone 8.1 (expresses PDGF-A dominant-negative)
Keywords = bioinformatics
Keywords = gene expression
Keywords = cancer
Keywords = platelet-derived growth factor
Keywords = sterol regulatory element binding protein
Keywords = glioblastoma multiformae
Keywords = microarray

source_name: U87 glioblastoma, clone 8.1 + PDGF


title: Clone 8.1 chip 3 no PDGF

source_name: U87 glioblastoma, clone 8.1 no PDGF


title: Clone 8.1 no PDGF


title: Clone 3.3 chip 2

description:
U87 glioblastoma cell, clone 3.3 (neo-resistant, negative control)
Keywords = bioinformatics
Keywords = gene expression
Keywords = cancer
Keywords = platelet-derived growth factor
Keywords = sterol regulatory element binding protein
Keywords = glioblastoma multiformae
Keywords = microarray

source_name: U87 glioblastoma, clone 3.3


title: Unrelated Male (M3)


title: Clone 8.1 chip 1 no PDGF


title: Clone 3.3 chip 3

description:
U87 glioblastoma cell, clone 3.3 neo resistant negative control
Keywords = bioinformatics
Keywords = gene expression
Keywords = cancer
Keywords = platelet-derived growth factor
Keywords = sterol regulatory element binding protein
Keywords = glioblastoma multiformae
Keywords = microarray


title: Clone 8.1 plus PDGF chip 2


title: Clone 3.1 chip 2

description:
U87 glioblastoma cell, clone 3.1 (neo-resistant negative control)
Keywords = bioinformatics
Keywords = gene expression
Keywords = cancer
Keywords = platelet-derived growth factor
Keywords = sterol regulatory element binding protein
Keywords = glioblastoma multiformae
Keywords = microarray

source_name: U87 glioblastoma, clone 3.1


title: Clone 3.1 chip 1


title: Unrelated Female F2 (F4)

source_name: Whole Blood


title: A549 lung pneumocytes cell line infected with PAK strain (needle complex deleted) Pseudomonas aeruginosa, replicate 2

city: Boston

first: Atul

last: Butte

state: MA

address: 300 Longwood Avenue

institute: Children's Hospital, Boston

description:
The A549 cells (ATCC CCL 165), a human lung carcinoma cell line, were grown in RPMI medium 1640 (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum, 24 mM HEPES and 2 mM L-glutamine and maintained at 37 degrees C in 5% CO2. Cells that were passaged 86-99 times were used for all experiments. Prior to each experiment, the cells were washed 2 times in Hank’s Balanced Salt Solution and incubated for 12-14 hrs in serum-free RPMI medium 1640 supplemented with 24 mM HEPES and 2 mM L-glutamine. The media was replaced again with fresh serum-free media just prior to addition of bacteria. The bacteria were grown in Luria-Bertani broth until mid-log phase (OD600 ~2.0), gently washed twice in PBS and then added to the flask containing A549 cells at a multiplicity of infection of 50:1 bacterial to A549 cells. Total RNA was isolated as previously described. PolyA enrichment was accomplished by oligo(dT)-cellulose selection using the Poly(A)Pure Kit (Ambion). PolyA enriched RNA was used to synthesize double stranded cDNA according to the Affymetrix supplied protocol (Affymetrix, Inc.). The first strand synthesis reaction was accomplished using 2 mcg RNA, SuperScript II Reverse Transcriptase (Invitrogen) and T7-(dT)24 primer (Genset Corp.) A second strand synthesis reaction followed using E. coli DNA ligase, E. coli DNA polymerase I and E. coli RNase H (Invitrogen). The double stranded cDNA was phenol extracted and used as template in an in vitro T7 transcription reaction using the MEGAscript T7 high yield transcription kit (Ambion) and biotinylated nucleotides Biotin-11-CTP, Biotin-16-UTP (NEN, Perkin-Elmer, Boston, MA). A 20 mcg cRNA aliquot was fragmented in 1X fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc) at 94 degrees C for 35 min. To check the quality of each sample, the cDNA, full length and fragmented cRNA were analyzed by electrophoresis on a 1% Agarose-TAE gel. 15 mcg of the fragmented cRNA were hybridized to an Affymetrix human GeneChip probe array U95Av2 for 16 hours at 45 degrees C. The probe arrays were washed, stained and scanned in an Affymetrix fluidics station and scanner following the manufacturer’s protocols. Raw image analysis was performed using the Affymetrix Microarray Suite v5.0 software.
Keywords = Pseudomonas aeruginosa
Keywords = A549 human lung carcinoma cell line
Keywords = cystic fibrosis

source_name: A549 lung pneumocytes cell line


title: A549 lung pneumocytes cell line infected with PAK strain (needle complex deleted) Pseudomonas aeruginosa, replicate 1


title: A549 lung pneumocytes cell line infected with wildtype PAK strain Pseudomonas aeruginosa, replicate 2

description:
The A549 cells (ATCC CCL 165), a human lung carcinoma cell line, were grown in RPMI medium 1640 (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum, 24 mM HEPES and 2 mM L-glutamine and maintained at 37 degrees C in 5% CO2. Cells that were passaged 86-99 times were used for all experiments. Prior to each experiment, the cells were washed 2 times in Hank’s Balanced Salt Solution and incubated for 12-14 hrs in serum-free RPMI medium 1640 supplemented with 24 mM HEPES and 2 mM L-glutamine. The media was replaced again with fresh serum-free media just prior to addition of bacteria. The bacteria were grown in Luria-Bertani broth until mid-log phase (OD600 ~2.0), gently washed twice in PBS and then added to the flask containing A549 cells at a multiplicity of infection of 50:1 bacterial to A549 cells. Total RNA was isolated as previously described. PolyA enrichment was accomplished by oligo(dT)-cellulose selection using the Poly(A)Pure Kit (Ambion). PolyA enriched RNA was used to synthesize double stranded cDNA according to the Affymetrix supplied protocol (Affymetrix, Inc.). The first strand synthesis reaction was accomplished using 2 µg RNA, SuperScript II Reverse Transcriptase (Invitrogen) and T7-(dT)24 primer (Genset Corp.) A second strand synthesis reaction followed using E. coli DNA ligase, E. coli DNA polymerase I and E. coli RNase H (Invitrogen). The double stranded cDNA was phenol extracted and used as template in an in vitro T7 transcription reaction using the MEGAscript T7 high yield transcription kit (Ambion) and biotinylated nucleotides Biotin-11-CTP, Biotin-16-UTP (NEN, Perkin-Elmer, Boston, MA). A 20 mcg cRNA aliquot was fragmented in 1X fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc) at 94 degrees C for 35 min. To check the quality of each sample, the cDNA, full length and fragmented cRNA were analyzed by electrophoresis on a 1% Agarose-TAE gel. 15 mcg of the fragmented cRNA were hybridized to an Affymetrix human GeneChip probe array U95Av2 for 16 hours at 45 degrees C. The probe arrays were washed, stained and scanned in an Affymetrix fluidics station and scanner following the manufacturer’s protocols. Raw image analysis was performed using the Affymetrix Microarray Suite v5.0 software.
Keywords = Pseudomonas aeruginosa
Keywords = A549 human lung carcinoma cell line
Keywords = cystic fibrosis


title: A549 lung pneumocytes cell line infected with PAK strain (exoS, exoY deleted) Pseudomonas aeruginosa, replicate 2


title: A549 lung pneumocytes cell line infected with wildtype PAK strain Pseudomonas aeruginosa, replicate 3


title: Clone 8.1 plus PDGF chip 3


title: A549 lung pneumocytes cell line infected with PAK strain (exoT, exoY deleted) Pseudomonas aeruginosa, replicate 2


title: A549 lung pneumocytes cell line infected with PAK strain (exoS, exoT deleted) Pseudomonas aeruginosa, replicate 1


title: A549 lung pneumocytes cell line infected with PAK strain (exoS, exoT deleted) Pseudomonas aeruginosa, replicate 2


title: A549 lung pneumocytes cell line infected with PAK strain (exoS, exoT, exoY deleted) Pseudomonas aeruginosa, replicate 2


title: A549 lung pneumocytes cell line infected with PAK strain (exoT, exoY deleted) Pseudomonas aeruginosa, replicate 1


title: A549 lung pneumocytes cell line infected with PAK strain (exoS, exoY deleted) Pseudomonas aeruginosa, replicate 1


title: Clone 3.3 chip 1

description:
U87 glioblastoma cell, clone 3.3 (neo-resistant negative control)
Keywords = bioinformatics
Keywords = gene expression
Keywords = cancer
Keywords = platelet-derived growth factor
Keywords = sterol regulatory element binding protein
Keywords = glioblastoma multiformae
Keywords = microarray


title: A549 lung pneumocytes cell line infected with PAK strain (exoS, exoT, exoY deleted) Pseudomonas aeruginosa, replicate 1


title: A549 lung pneumocytes cell line infected with wildtype PAK strain Pseudomonas aeruginosa, replicate 1


title: Clone 3.1 chip 3


title: Baseline uninfected A549 lung pneumocytes cell line, replicate 3

description:
The A549 cells (ATCC CCL 165), a human lung carcinoma cell line, were grown in RPMI medium 1640 (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum, 24 mM HEPES and 2 mM L-glutamine and maintained at 37 degrees C in 5% CO2. Cells that were passaged 86-99 times were used for all experiments. Prior to each experiment, the cells were washed 2 times in Hank’s Balanced Salt Solution and incubated for 12-14 hrs in serum-free RPMI medium 1640 supplemented with 24 mM HEPES and 2 mM L-glutamine. The media was replaced again with fresh serum-free media just prior to addition of bacteria. The bacteria were grown in Luria-Bertani broth until mid-log phase (OD600 ~2.0), gently washed twice in PBS and then added to the flask containing A549 cells at a multiplicity of infection of 50:1 bacterial to A549 cells.

Total RNA was isolated as previously described. PolyA enrichment was accomplished by oligo(dT)-cellulose selection using the Poly(A)Pure Kit (Ambion). PolyA enriched RNA was used to synthesize double stranded cDNA according to the Affymetrix supplied protocol (Affymetrix, Inc.). The first strand synthesis reaction was accomplished using 2 µg RNA, SuperScript II Reverse Transcriptase (Invitrogen) and T7-(dT)24 primer (Genset Corp.) A second strand synthesis reaction followed using E. coli DNA ligase, E. coli DNA polymerase I and E. coli RNase H (Invitrogen). The double stranded cDNA was phenol extracted and used as template in an in vitro T7 transcription reaction using the MEGAscript T7 high yield transcription kit (Ambion) and biotinylated nucleotides Biotin-11-CTP, Biotin-16-UTP (NEN, Perkin-Elmer, Boston, MA). A 20 mcg cRNA aliquot was fragmented in 1X fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc) at 94 degrees C for 35 min. To check the quality of each sample, the cDNA, full length and fragmented cRNA were analyzed by electrophoresis on a 1% Agarose-TAE gel. 15 mcg of the fragmented cRNA were hybridized to an Affymetrix human GeneChip probe array U95Av2 for 16 hours at 45 degrees C. The probe arrays were washed, stained and scanned in an Affymetrix fluidics station and scanner following the manufacturer’s protocols. Raw image analysis was performed using the Affymetrix Microarray Suite v5.0 software.
Keywords = Pseudomonas aeruginosa
Keywords = A549 human lung carcinoma cell line
Keywords = cystic fibrosis


title: Baseline uninfected A549 lung pneumocytes cell line, replicate 2

description:
The A549 cells (ATCC CCL 165), a human lung carcinoma cell line, were grown in RPMI medium 1640 (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum, 24 mM HEPES and 2 mM L-glutamine and maintained at 37 degrees C in 5% CO2. Cells that were passaged 86-99 times were used for all experiments. Prior to each experiment, the cells were washed 2 times in Hank’s Balanced Salt Solution and incubated for 12-14 hrs in serum-free RPMI medium 1640 supplemented with 24 mM HEPES and 2 mM L-glutamine. The media was replaced again with fresh serum-free media just prior to addition of bacteria. The bacteria were grown in Luria-Bertani broth until mid-log phase (OD600 ~2.0), gently washed twice in PBS and then added to the flask containing A549 cells at a multiplicity of infection of 50:1 bacterial to A549 cells.
Keywords = Pseudomonas aeruginosa
Keywords = A549 human lung carcinoma cell line
Keywords = cystic fibrosis


title: HUVEC3

status: Public on Dec 09 2004

city: Frankfurt

first: Carmen

last: Urbich

country: Germany

institute: Molecular Cardiology

description: Human umbilical vein endothelial cell mRNA

source_name: Human umbilical vein endothelial cells


title: monocyte 2

description: Human CD14+ monocytes mRNA

source_name: Human CD14+ monocytes


title: Baseline uninfected A549 lung pneumocytes cell line, replicate 1


title: monocyte 3

description: Human CD14+ monocytes mRNA


title: EPC3

description: Human EPC mRNA

source_name: Human EPC


title: monocytes 1

description: Human CD14+ monocyte mRNA

source_name: human CD14+ monocytes


title: GEIM 39 on u95Av2

status: Public on Dec 08 2004

city: Cambridge

first: Sek Won

last: Kong

address: 7 Divinity Avenue

institute: Harvard University

description: The dataset consists of a set of 14 human muscle biopsy samples from patients with inflammatory myopathies that were hybridized on both HG-U95Av2 and HG-U133A human arrays.

source_name: Human, muscle, dermatomyositis


title: HUVEC1


title: EPC2

description: Human EPC mRNA


title: EPC1

description: human EPC mRNA

source_name: human EPC


title: GEIM 36 on u95Av2

source_name: Human, muscle, inclusion body myositis


title: GEIM 38 on u95Av2


title: GEIM 20 on u95Av2


title: GEIM 21 on u95Av2

source_name: Human, muscle, inflammatory myopathy


title: GEIM 27 on u95Av2


title: GEIM 16 on u95Av2

source_name: Human, muscle, polymyositis


title: HUVEC2


title: GEIM 12 on u95Av2


title: GEIM 19 on u95Av2


title: GEIM 30 on u95Av2


title: GEIM 17 on u95Av2


title: GEIM 9 on u95Av2


title: GEIM 3 on u95Av2

description:
The dataset consists of a set of 14 human muscle biopsy samples from patients with inflammatory myopathies that were hybridized on both HG-U95Av2 and HG-U133A human arrays.
Lot batch = GEIM 3


title: PGA-N-0915

status: Public on Dec 03 2004

first: Martina

last: Schinke

address: 7 Divinity Ave

department: Bauer Center for Genomic Research

description:
LV biopsies in patients (pts) with LV hypertrophy (H) due to aortic stenosis (AS, n=9) and in congestive cardiomyopathy (CCMP,n=6) pts. Pts with coronary artery disease and normal LV function served as controls (C,n=4). LV biopsies were obtained at cardiac catheterization in CCMP pts and at cardiac surgery in AS and C pts.
Keywords = congestive cardiomyopathy, aortic stenosis, heart failure, cardiac hypertrophy

source_name: Heart biopsy


title: PGA-CCMP-0811


title: PGA-N-1303


title: PGA-CCMP-0120


title: GEIM 7 on u95Av2


title: PGA-N-0821


title: PGA-CCMP-0718


title: PGA-CCMP-1109


title: PGA-N-0106


title: PGA-CCMP-1003


title: PGA-CCMP-0218


title: PGA-AS-1805


title: PGA-AS-2604


title: PGA-AS-0806


title: PGA-AS-0511


title: PGA-AS-2708


title: PGA-AS-1504


title: Patient 16, Visit 2, Time of treatment 8 weeks, File nt110604

status: Public on Dec 01 2004

city: Collegeville

first: Michael

middle: E.

last: Burczynski

state: PA

address: 500 Arcola Road

department: Pharmacogenomic Biomarkers

institute: Wyeth

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 16
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 25813
Cummulative AUC sum : 115657

source_name: Peripheral Blood Mononuclear Cells (PBMC)


title: Patient 26, Visit 2, Time of treatment 8 weeks, File nt092603

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 26
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 25223
Cummulative AUC sum : 112955


title: PGA-AS-2111


title: Patient 16, Visit 3, Time of treatment 16 weeks, File nt110603

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 16
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 48111
Cummulative AUC sum : 216570


title: Patient 29, Visit 2, Time of treatment 8 weeks, File nt092609

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 29
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 9890
Cummulative AUC sum : 40226


title: Patient 42, Visit 2, Time of treatment 8 weeks, File nt092608

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 42
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 10123
Cummulative AUC sum : 41994


title: Patient 45, Visit 3, Time of treatment 16 weeks, File nt080213

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 45
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 21933
Cummulative AUC sum : 87279


title: Patient 45, Visit 1, Time of treatment 0 weeks, File nt062113

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 45
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 46, Visit 2, Time of treatment 8 weeks, File nt092606

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 46
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 14419
Cummulative AUC sum : 61747


title: Patient 45, Visit 2, Time of treatment 8 weeks, File nt080211

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 45
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 11037
Cummulative AUC sum : 43710


title: Patient 41, Visit 3, Time of treatment 16 weeks, File nt092611

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 41
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 23078
Cummulative AUC sum : 123101


title: Patient 44, Visit 2, Time of treatment 8 weeks, File nt092604

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 44
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 17836
Cummulative AUC sum : 91887


title: Patient 43, Visit 1, Time of treatment 0 weeks, File nt062107

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 43
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 43, Visit 2, Time of treatment 8 weeks, File nt110605

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 43
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 9247
Cummulative AUC sum : 41894


title: Patient 37, Visit 2, Time of treatment 8 weeks, File nt090711

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 37
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 9503
Cummulative AUC sum : 50707


title: Patient 43, Visit 3, Time of treatment 16 weeks, File nt100407

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 43
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 17236
Cummulative AUC sum : 78448


title: Patient 40, Visit 2, Time of treatment 8 weeks, File nt110707

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 40
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 11859
Cummulative AUC sum : 114073


title: Patient 37, Visit 3, Time of treatment 16 weeks, File nt090712

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 37
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 19908
Cummulative AUC sum : 106451


title: Patient 40, Visit 3, Time of treatment 16 weeks, File nt110706

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 40
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 23371
Cummulative AUC sum : 221496


title: Patient 39, Visit 1, Time of treatment 0 weeks, File nt06211n

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 39
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 37, Visit 1, Time of treatment 0 weeks, File nt100408

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 37
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 36, Visit 2, Time of treatment 8 weeks, File nt090706

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 36
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 23227
Cummulative AUC sum : 77856


title: Patient 34, Visit 2, Time of treatment 8 weeks, File nt090713

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 34
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 6514
Cummulative AUC sum : 26058


title: Patient 35, Visit 1, Time of treatment 0 weeks, File nt06214a

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 35
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 32, Visit 1, Time of treatment 0 weeks, File nt090401

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 32
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 36, Visit 1, Time of treatment 0 weeks, File nt06213a

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 36
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 32, Visit 2, Time of treatment 8 weeks, File nt080209

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 32
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 9734
Cummulative AUC sum : 34815


title: Patient 29, Visit 2, Time of treatment 8 weeks, File nt090703

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 29
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 14504
Cummulative AUC sum : 54422


title: Patient 36, Visit 3, Time of treatment 16 weeks, File nt090707

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 36
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 45026
Cummulative AUC sum : 151178


title: Patient 27, Visit 2, Time of treatment 8 weeks, File nt080206

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 27
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 4513
Cummulative AUC sum : 24423


title: Patient 28, Visit 1, Time of treatment 0 weeks, File nt06215a

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 28
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 34, Visit 1, Time of treatment 0 weeks, File nt06216b

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 34
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 29, Visit 1, Time of treatment 0 weeks, File nt06211a

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 29
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 30, Visit 2, Time of treatment 8 weeks, File nt090709

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 30
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 15836
Cummulative AUC sum : 90203


title: Patient 29, Visit 3, Time of treatment 16 weeks, File nt110703

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 29
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 27048
Cummulative AUC sum : 100770


title: Patient 39, Visit 2, Time of treatment 8 weeks, File nt092602

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 39
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 7991
Cummulative AUC sum : 33072


title: Patient 33, Visit 2, Time of treatment 8 weeks, File nt092610

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 33
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 19728
Cummulative AUC sum : 83924


title: Patient 27, Visit 3, Time of treatment 16 weeks, File nt072711

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 27
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 9279
Cummulative AUC sum : 48930


title: Patient 34, Visit 3, Time of treatment 16 weeks, File nt090714

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 34
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 10878
Cummulative AUC sum : 42879


title: Patient 30, Visit 3, Time of treatment 16 weeks, File nt090710

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 30
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 32827
Cummulative AUC sum : 187124


title: Patient 26, Visit 2, Time of treatment 8 weeks, File nt100406

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 26
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 10843
Cummulative AUC sum : 58172


title: Patient 23, Visit 2, Time of treatment 8 weeks, File nt080205

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 23
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 16666
Cummulative AUC sum : 63994


title: Patient 25, Visit 3, Time of treatment 16 weeks, File nt100405

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 25
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 20575
Cummulative AUC sum : 70737


title: Patient 21, Visit 3, Time of treatment 16 weeks, File nt110602

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 21
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 43076
Cummulative AUC sum : 137732


title: Patient 23, Visit 1, Time of treatment 0 weeks, File nt080204

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 23
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 25, Visit 2, Time of treatment 8 weeks, File nt110601

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 25
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 10353
Cummulative AUC sum : 35434


title: Patient 19, Visit 1, Time of treatment 0 weeks, File nt06212a

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 19
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 22, Visit 2, Time of treatment 8 weeks, File nt092601

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 22
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 9924
Cummulative AUC sum : 35005


title: Patient 26, Visit 3, Time of treatment 16 weeks, File nt110708

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 26
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 20211
Cummulative AUC sum : 108951


title: Patient 16, Visit 3, Time of treatment 16 weeks, File nt100404

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 16
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 29158
Cummulative AUC sum : 106848


title: Patient 21, Visit 2, Time of treatment 8 weeks, File nt090705

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 21
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 21676
Cummulative AUC sum : 69004


title: Patient 15, Visit 3, Time of treatment 16 weeks, File nt090708

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 15
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 18114
Cummulative AUC sum : 59772


title: Patient 16, Visit 2, Time of treatment 8 weeks, File nt090704

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 16
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 17098
Cummulative AUC sum : 62668


title: Patient 20, Visit 2, Time of treatment 8 weeks, File nt092605

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 20
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 8834
Cummulative AUC sum : 45715


title: Patient 12, Visit 1, Time of treatment 0 weeks, File nt062112

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 12
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 17, Visit 1, Time of treatment 0 weeks, File nt06218a

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 17
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 14, Visit 2, Time of treatment 8 weeks, File nt110702

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 14
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 23717
Cummulative AUC sum : 80750


title: Patient 15, Visit 2, Time of treatment 8 weeks, File nt110705

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 15
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 8848
Cummulative AUC sum : 29259


title: Patient 14, Visit 3, Time of treatment 16 weeks, File nt110701

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 14
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 51592
Cummulative AUC sum : 174708


title: Patient 17, Visit 2, Time of treatment 8 weeks, File nt080210

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 17
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 17259
Cummulative AUC sum : 70089


title: Patient 23, Visit 3, Time of treatment 16 weeks, File nt072709

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 23
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 28259
Cummulative AUC sum : 108365


title: Patient 14, Visit 1, Time of treatment 0 weeks, File nt080201

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 14
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 9, Visit 1, Time of treatment 0 weeks, File nt100409

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 9
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 7, Visit 3, Time of treatment 16 weeks, File nt072712

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 7
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 11808
Cummulative AUC sum : 49456


title: Patient 8, Visit 2, Time of treatment 8 weeks, File nt110704

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 8
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 35366
Cummulative AUC sum : 112213


title: Patient 6, Visit 2, Time of treatment 8 weeks, File nt092612

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 6
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 8258
Cummulative AUC sum : 33339


title: Patient 5, Visit 2, Time of treatment 8 weeks, File nt080202

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 5
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 12168
Cummulative AUC sum : 49049


title: Patient 8, Visit 3, Time of treatment 16 weeks, File nt090702

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 8
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 63336
Cummulative AUC sum : 200243


title: Patient 8, Visit 1, Time of treatment 0 weeks, File nt062109

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 8
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 6, Visit 3, Time of treatment 16 weeks, File nt092613

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 6
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 16411
Cummulative AUC sum : 66573


title: Patient 3, Visit 3, Time of treatment 16 weeks, File nt100403

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 3
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 59911
Cummulative AUC sum : 224199


title: Patient 5, Visit 1, Time of treatment 0 weeks, File nt072707

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 5
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 7, Visit 2, Time of treatment 8 weeks, File nt080208

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 7
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 5181
Cummulative AUC sum : 21591


title: Patient 11, Visit 1, Time of treatment 0 weeks, File nt072706

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 11
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 3, Visit 2, Time of treatment 8 weeks, File nt100402

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 3
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 34721
Cummulative AUC sum : 129638


title: Patient 5, Visit 3, Time of treatment 16 weeks, File nt072708

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 5
Donor disease : Renal Cell Carcinoma
Visit number : 3
Treatment : CCI-779
Time of treatment : 16 weeks
CCI Cummulative AUC : 21772
Cummulative AUC sum : 87676


title: Patient 6, Visit 1, Time of treatment 0 weeks, File nt062111

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 6
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 1, Visit 2, Time of treatment 8 weeks, File nt092607

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 1
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 16755
Cummulative AUC sum : 57822


title: Patient 3, Visit 1, Time of treatment 0 weeks, File nt100401

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 3
Donor disease : Renal Cell Carcinoma
Visit number : 1
Treatment : CCI-779
Time of treatment : 0 weeks
CCI Cummulative AUC : N/A
Cummulative AUC sum : N/A


title: Patient 4, Visit 2, Time of treatment 8 weeks, File nt080212

description:
PBMCs from Renal Cell Carcinoma subjects. Samples collected over time as subject was treated with CCI-779
Donor number : 4
Donor disease : Renal Cell Carcinoma
Visit number : 2
Treatment : CCI-779
Time of treatment : 8 weeks
CCI Cummulative AUC : 29281
Cummulative AUC sum : 124198


title: 17Mdm+serum

city: Philadelphia

first: Andrew

middle: V.

last: Albright

address: 255 CRB  415 Curie Blvd

department: Neurology

institute: University of Pennsylvania

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Activated monocyte derived-macrophages
Sample 17

source_name: Monocyte derived-macrophages


title: 17Mdm-serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Non activated monocyte derived-macrophages
sample 17


title: 14Mdm-serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
non-activated monocyte derived-macrophages
Sample 14


title: 14Mdm+serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Activated monocyte derived-macrophages


title: 8Mdm+serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Activated Monocyte-derived macrophages
Sample 8
Keywords = activated
Keywords = microglia

source_name: Monocyte-derived macrophages


title: Patient 5 replicate 3 (5-3)

status: Public on Nov 05 2004

city: Pittsburgh

middle: Gerard

last: Peters

department: Medicine

institute: University of Pittsburgh

description: Use Of Expression Arrays To Identify Genes From Ovarian Cancer Cells That Are Associated With Carboplatin Sensitivity And Resistance

source_name: ovarian carcinoma


title: 18Mix+serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Mixed glial cells (predominatly microglia)
Sample 18
Keywords = activated
Keywords = microglia

source_name: Mixed glial cells (predominantly microglia)


title: Patient 5 replicate 1 (5-1)


title: Patient 4 replicate 2 (4-2)


title: 1Mix-serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Non-activated mixed glial cells (predominatly microglia)
Sample 1
Keywords = activated
Keywords = microglia


title: 8Mdm-serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Non-activated Monocyte-derived macrophages
Sample 8
Keywords = activated
Keywords = microglia


title: Patient 4 replicate 3 (4-3)


title: 18Mix-serum


title: 16Mix-serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Mixed glial cells (predominatly microglia)
Sample 16
Keywords = activated
Keywords = microglia


title: patient 6 replicate 3 (6-3)


title: 16Mix+serum


title: 7Mix-serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Non-activated mixed glial cells (predominantly microglia)
Sample 7
Keywords = activated
Keywords = microglia


title: 1Mix+serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Activated mixed glial cells (predominatly microglia)
Sample 1
Keywords = activated
Keywords = microglia


title: Patient 5 replicate 2 (5-2)


title: patient 6 replicate 1 (6-1)


title: patient 6 replicate 2 (6-2)


title: Patient 4 replicate 1 (4-1)


title: 7Mix+serum

description:
From 'Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression.'
Activated mixed glial cells (predominantly microglia)
Sample 7
Keywords = activated
Keywords = microglia


title: Patient 3 replicate 3 (3-3)


title: Patient 3 replicate 2 (3-2)


title: Patient 1 replicate 2 (1-2)


title: Patient 2 replicate 1 (2-1)


title: pool3, IFN-g primed, 100 U/ml IFN-g for 3 h

city: New York

first: Xiaoyu

last: Hu

state: NY

address: 535 East 70th Street

department: Research

institute: Hospital for Special Surgery

description: 3 U/ml of IFN-g primed macrophages stimulated with 100 U/ml of IFN-g for 3 h

source_name: primary human CD14+ macrophages


title: Patient 1 replicate 3 (1-3)


title: Patient 3 replicate 1 (3-1)


title: Patient 2 replicate 3 (2-3)


title: pool3, IFN-g primed, 100 U/ml IFN-g for 24 h

description: 3 U/ml of IFN-g primed macrophages stimulated with 100 U/ml of IFN-g for 24 h


title: pool3, control, 100 U/ml IFN-g for 24 h

description: control M-CSF macrophages stimulated with 100 U/ml of IFN-g for 24 h


title: pool2, control, 100 U/ml IFN-g for 24 h


title: pool3, IFN-g primed, unstimulated

description: human blood monocytes cultured with 10 ng/ml of M-CSF and 3 U/ml of IFN-g for 48 h


title: pool2, IFN-g primed, unstimulated


title: pool2, IFN-g primed, 100 U/ml IFN-g for 3 h


title: pool2, control, unstimulated

description: human blood monocytes cultured with 10 ng/ml of M-CSF for 48 h


title: pool3, control, unstimulated


title: pool3, control, 100 U/ml IFN-g for 3 h

description: control M-CSF macrophages stimulated with 100 U/ml of IFN-g for 3 h


title: pool2, control, 100 U/ml IFN-g for 3 h


title: Patient 1 replicate 1 (1-1)


title: Patient 2 replicate 2 (2-2)


title: pool2, IFN-g primed, 100 U/ml IFN-g for 24 h


title: pool1, IFN-g primed, 100 U/ml IFN-g for 3 h


title: pool1, IFN-g primed, 100 U/ml IFN-g for 24 h


title: IPF3 TGFbeta-treated

status: Public on Nov 02 2004

city: London

first: Elisabetta

middle: Augusta

last: Renzoni

address: EKB, 1B Manresa Rd

department: Dept of Occupational and Environmental Medicine

country: United Kingdom

institute: Royal Brompton Hospital/Imperial College of Science, Technology and Medicine

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (IPF3) with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern on biopsy). Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems) in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from a patient (IPF3) with idiopathic pulmonary fibrosis


title: pool1, control, 100 U/ml IFN-g for 3 h


title: pool1, IFN-g primed, unstimulated


title: pool1, control, 100 U/ml IFN-g for 24 h


title: pool1, control, unstimulated


title: FASSc3 medium only

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (FASSc3) with fibrosing alveolitis associated with systemic sclerosis. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from a patient (FASSc3) with fibrosing alveolitis associated with systemic sclerosis


title: IPF1 TGFbeta-treated

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (IPF1) with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern on biopsy). Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems)in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from a patient (IPF1) with idiopathic pulmonary fibrosis


title: FASSc3 TGFbeta-treated

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (FASSc3) with fibrosing alveolitis associated with systemic sclerosis. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems) in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.


title: Control 3 medium only

description: mRNA extracted from control lung fibroblasts derived from normal periphery of resected tumor. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: control lung fibroblasts


title: IPF2 medium only

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (IPF2) with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern on biopsy). Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from a patient (IPF2) with idiopathic pulmonary fibrosis


title: FASSc2 TGFbeta-treated

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (FASSc2) with fibrosing alveolitis associated with systemic sclerosis. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems) in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from a patient (FASSc2) with fibrosing alveolitis associated with systemic sclerosis


title: Control 3 TGFbeta-treated

description: mRNA extracted from control lung fibroblasts derived from normal periphery of resected tumor. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems) in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.


title: IPF2 TGFbeta-treated

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (IPF2) with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern on biopsy). Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems) in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.


title: IPF3 medium only

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (IPF3) with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern on biopsy). Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.


title: IPF1 medium only

description: mRNA extracted from lung fibroblasts derived from open lung biopsies of a patient (IPF1) with idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern on biopsy). Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from a patient with idiopathic pulmonary fibrosis (IPF1)


title: Control 2 TGFbeta-treated


title: Control 2 medium only


title: FASSc1 medium only

description: mRNA extracted from  lung fibroblasts derived from open lung biopsies of a patient (FASSc1) with fibrosing alveolitis associated with systemic sclerosis. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from patient with fibrosing alveolitis associated with systemic sclerosis


title: FASSc1 TGFbeta-treated

description: mRNA extracted from  lung fibroblasts derived from open lung biopsies of a patient (FASSc1) with fibrosing alveolitis associated with systemic sclerosis. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to 4 ng/ml of activated TGF-ß1 (R&D Systems) in serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.

source_name: lung fibroblasts from patients with fibrosing alveolitis associated with systemic sclerosis


title: FASSc2 medium only

description: mRNA extracted from  lung fibroblasts derived from open lung biopsies of a patient (FASSc2) with fibrosing alveolitis associated with systemic sclerosis. Lung fibroblasts were grown to confluence in DMEM with 10% fetal calf serum. At confluence, lung fibroblasts were serum-deprived overnight, and exposed to  serum-free culture-medium with the addition of 0.1% BSA for 4 hours. At the end of treatment period total RNA was harvested, quantified, and integrity was verified by denaturing gel electrophoresis.


title: Control 1 TGFbeta-treated

source_name: control lung fibroblasts treated with TGFbeta


title: Control 1 medium only

source_name: lung fibroblasts


title: M091_setB_4hr

status: Public on Oct 28 2004

first: Agnes

last: Viale

address: 1275 York Avenue

department: Molecular Biology

institute: Memorial Sloan Kettering Cancer Center

description:
Total RNA
RNeasy extraction
Two rounds amplification (RT+IVT) Ambion MessageAmp kit

source_name: M091 cell line, TGFbeta treatment 4 hrs


title: M091_setC_4hr

source_name: M091 cell line, TGFbeta treatment 4hr


title: M091_setC_2hr

source_name: M091 cell line,TGFbeta treatment  2hrs


title: M091_setA_2hr

source_name: M091 cell line, TGFbeta treatment 2hrs


title: body wall 23

status: Public on Oct 27 2004

city: Cleveland

first: Feng-Qi

last: An

state: OH

address: 10900 Euclid Avenue

department: Pathology

institute: Case Western Reserve University

description:
Gene expression profiling in Telomerase-Immortalized Human umbilical Vein Endothelial (TIVE) cell line with infection by KSHV for ten months.
Gene expression profiling of two time points on TIVE cells after infection by KSHV compare to TIVE cell without infection by KSHV to figure out the changed genes on TIVE cell under latent infection of KSHV.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = TIVE cell,KSHV,LANA,Gene expression profiling.

source_name: TIVE - infected by KSHV for 10 months


title: body wall 16

description:
Gene expression profiling in 293/Tet-On/LANA cell line after recombinant LANA protein expression for 30 hours.
Gene expression profiling of two time points after inducing recombinant LANA protein expression when compare to no inducing 293/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = 293/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: body wall 19

description:
Gene expression profiling in Jurkat/Tet-On/LANA cell line after recombinant LANA protein expression for 42 hours.
Gene expression profiling of three time points after inducing recombinant LANA protein expression when compare to no inducing Jurkat/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = Jurkat/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.

source_name: Jurkat/Tet-On/LANA cell after recombinant LANA protein expression for 42 hours.


title: body wall 15

description:
Gene expression profiling in 293/Tet-On/LANA cell line after recombinant LANA protein expression for 18 hours.
Gene expression profiling of two time points after inducing recombinant LANA protein expression when compare to no inducing 293/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = 293/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: body wall 21

description:
Gene expression profiling in Telomerase-Immortalized Human umbilical Vein Endothelial (TIVE) cell line without infection by KSHV.
Gene expression profiling of two time points on TIVE cells after infection by KSHV compare to TIVE cell without infection by KSHV to figure out the changed genes on TIVE cell under latent infection of KSHV.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = TIVE cell,KSHV,LANA,Gene expression profiling.

source_name: TIVE - not infected


title: body wall 20

description:
Gene expression profiling in Jurkat/Tet-On/LANA cell line after no recombinant LANA protein expression at the same growth condition as LANA expression group.
Gene expression profiling of three time points after inducing recombinant LANA protein expression when compare to no inducing Jurkat/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = Jurkat/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.

source_name: Jurkat/Tet-On/LANA cell after no recombinant LANA protein expression


title: body wall 14

description:
Gene expression profiling in 293/Tet-On/LANA cell line after no recombinant LANA protein expression at the same growth condition as LANA expression group.
Gene expression profiling of two time points after inducing recombinant LANA protein expression when compare to no inducing 293/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = 293/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: body wall 22

description:
Gene expression profiling in Telomerase-Immortalized Human umbilical Vein Endothelial (TIVE) cell line with infection by KSHV for three months.
Gene expression profiling of two time points on TIVE cells after infection by KSHV compare to TIVE cell without infection by KSHV to figure out the changed genes on TIVE cell under latent infection of KSHV.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = TIVE cell,KSHV,LANA,Gene expression profiling.

source_name: TIVE - infected by KSHV for 3 months


title: body wall 13

description:
Gene expression profiling in BJAB/Tet-On/LANA cell line after no recombinant LANA protein expression for 36 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: M091_setC_0hr

source_name: M091 cell line, no TGFbeta Treatment


title: M091_setB_2hr


title: M091_setB_0hr

source_name: M091 cells, no TGFbeta treatment


title: body wall 12

description:
Duplicated gene expression profiling in BJAB/Tet-On/LANA cell line after no recombinant LANA protein expression for 12 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.

source_name: BJAB/Tet-On/LANA cell line after no recombinant LANA protein expression for 12 hours, duplicated.


title: M091_setA_0hr

source_name: m091 cell line, no TGFbeta treatment


title: body wall 9

description:
Gene expression profiling in BJAB/Tet-On/LANA cell line after recombinant LANA protein expression for 36 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: body wall 10

description:
Gene expression profiling in BJAB/Tet-On/LANA cell line after recombinant LANA protein expression for 48 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: body wall 8

description:
Gene expression profiling in BJAB/Tet-On/LANA cell line after recombinant LANA protein expression for 24 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.

source_name: BJAB /Tet-On/LANA cell line after recombinant LANA protein expression for 24 hours


title: body wall 18

description:
Gene expression profiling in Jurkat/Tet-On/LANA cell line after recombinant LANA protein expression for 30 hours.
Gene expression profiling of three time points after inducing recombinant LANA protein expression when compare to no inducing Jurkat/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = Jurkat/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.

source_name: Jurkat/Tet-On/LANA cell after recombinant LANA protein expression for 30 hours.


title: body wall 17

description:
Gene expression profiling in Jurkat/Tet-On/LANA cell line after recombinant LANA protein expression for 18 hours.
Gene expression profiling of three time points after inducing recombinant LANA protein expression when compare to no inducing Jurkat/Tet-On/LANA cell line to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = Jurkat/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.

source_name: Jurkat/Tet-On/LANA cell after recombinant LANA protein expression for 18 hours.


title: body wall 7

description:
Gene expression profiling in BJAB/Tet-On/LANA cell line after recombinant LANA protein expression for 12 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: body wall 11

description:
Gene expression profiling in BJAB/Tet-On/LANA cell line after no recombinant LANA protein expression for 12 hours.
Gene expression profiling of four time points after inducing recombinant LANA protein expression when compare to no inducing BJAB/Tet-On/LANA cells to figure out the changed genes under the latency-associate nuclear antigen (LANA) of KSHV expression.
RNA was extracted using RNAzol. Targets were produced using standard Affymetrix procedures from about 8ug of total RNA.
Keywords = BJAB/Tet-On/LANA cell,KSHV,LANA,Gene expression profiling.


title: Patient 2 Exercise 8 am

status: Public on Oct 14 2004

city: Claremont

first: Alexander

middle: C

last: Zambon

address: 517 Watson Drive

department: Biopharmaceutical Sciences

institute: Keck Graduate Institute

description:
5 healthy male volunteers exercised with the right leg at 2 pm. Biopsies were removed from the exercised and nonexercised leg 6h and 18h later
Keywords = Human
Keywords = resistance exercise
Keywords = muscle
Keywords = circadian

source_name: Vastus Lateralis


title: Patient 1 Nonexercised 8 am

source_name: Vastus Lateralus


title: Patient 3 Exercise 8 am


title: Patient 4 Exercise 8 am


title: Pateint 2 Exercise 8 pm


title: Patient 4 Exercise 8 pm


title: Patient 4 Nonexercised 8 am


title: Patient 1 Exercise 8 pm


title: Patient 3 Nonexercised 8 am


title: Patient 3 Nonexercise 8 pm

source_name: Vastus Lateralis Muscle


title: Patient 4 Nonexercise 8 pm


title: Patient 2 Nonexercised 8 am


title: Patient 1 Nonexercise 8 pm

source_name: vastus lateralis muscle


title: Patient 2 Nonexericse 8 pm


title: YT34-3

status: Public on Sep 09 2004

first: Ioannis

last: Tassiulas

institute: The Hospital for Special Surgery

description: Human peripheral blood monocytes cultured in the presence of hMCSF and IFN-gamma for two days.

source_name: Human Peripheral Blood Monocytes


title: YT34-1

description: Human peripheral blood monocytes cultured in the presence of hMCSF for two days.


title: Patient 3 Exercise 8 pm


title: YT30-4

description: Human peripheral blood monocytes cultured in the presence of hMCSF and IFN-gamma for two days and stimulated with IFN-alpha for three hours.


title: YT34-4


title: YT34-2

description: Human peripheral blood monocytes cultured in the presence of hMCSF for two days and stimulated with IFN-alpha for three hours.


title: YT30-1


title: YT30-3


title: RadS14-Mock

status: Public on Sep 06 2004

city: Stanford

first: Wan-Jen

last: Hong

address: 269 Campus Dr., CCSR Room 1140

department: Medicine/Biochemistry

institute: Stanford University School of Medicine

description:
Peripheral blood lymphocytes from a total of 57 patients were immortalized with Epstein-Barr virus.  Fourteen radiation-therapy patients suffered unusual levels of radiation toxicity (RadS).  Thirteen radiation-therapy patients with limited toxicity (RadC) were enrolled as controls.  Fifteen patients diagnosed with skin cancer before age 40 (SkCa) were used as a second group of controls.  Fifteen healthy subjects without any history of cancer (NoCa) were matched to the skin cancer patients and used as a third group of controls.

Cells were exposed to mock treatment (Mock), ultra-violet radiation (UV), or ionizing radiation (IR).  For UV radiation treatment, cells were exposed to 10 J/m^2 and harvested for RNA 24 hours later.  For IR treatment, cells were exposed to 5 Gy of IR and harvested for RNA 4 hours later.  For example, RadS1-Mock refers to cells from radiation sensitive patient 1 exposed to mock treatment.

Data were analyzed with Affymetrix MAS version 4.0.

Normalization – A reference data set was generated by averaging the expression of each gene over all data sets. The data for each hybridization were compared with the reference data set in a cube root scatter plot. A linear least-squares fit to the cube root scatter plot was then used to normalize each hybridization.
Keywords = Gene expression in lymphoid cells of cancer patients

source_name: Lymphoblastoid cells immortalized with Epstein-Barr virus


title: YT28-4


title: YT28-3


title: YT30-2


title: RadS12-UV


title: RadS14-UV


title: YT28-2


title: RadS13-Mock


title: RadS12-IR


title: RadS10-Mock


title: RadS11-IR


title: RadS10-IR


title: YT28-1


title: RadS10-UV


title: RadS11-UV


title: RadS12-Mock


title: RadS13-UV


title: RadS8-Mock


title: RadS7-UV


title: RadS8-UV


title: RadS9-Mock


title: RadS9-IR


title: RadS7-IR


title: RadS6-UV


title: RadS8-IR


title: RadS9-UV


title: RadS6-Mock


title: RadS6-IR


title: RadS5-UV


title: RadS4-Mock


title: RadS4-UV


title: RadS7-Mock


title: RadS5-IR


title: RadS5-Mock


title: RadS14-IR


title: RadS3-UV


title: RadS4-IR


title: RadS2-UV


title: RadS3-IR


title: RadS1-UV


title: RadS2-IR


title: RadS1-IR


title: RadS1-Mock


title: RadS3-Mock


title: RadC11-Mock


title: RadC12-UV


title: RadC11-IR


title: RadC13-IR


title: RadS2-Mock


title: RadC10-UV


title: RadC12-Mock


title: RadC13-Mock


title: RadC11-UV


title: RadC12-IR


title: RadC13-UV


title: RadC10-Mock


title: RadC10-IR


title: RadC9-IR


title: RadC9-UV


title: RadC5-Mock


title: RadC8-IR


title: RadC9-Mock


title: RadC8-Mock


title: RadC7-UV


title: RadC6-Mock


title: RadC6-UV


title: RadC5-UV


title: RadC4-UV


title: RadC6-IR


title: RadC7-IR


title: RadC5-IR


title: RadC4-IR


title: RadC8-UV


title: RadC7-Mock


title: RadC4-Mock


title: RadC3-UV


title: RadC3-Mock


title: RadS11-Mock


title: RadC3-IR


title: RadC2-Mock


title: RadC2-UV


title: SkCa15-UV


title: RadC1-UV


title: SkCa14-Mock


title: SkCa13-UV


title: RadC2-IR


title: SkCa14-IR


title: RadC1-IR


title: SkCa15-IR


title: SkCa13-IR


title: SkCa13-Mock


title: SkCa15-Mock


title: RadC1-Mock


title: SkCa12-UV


title: SkCa14-UV


title: SkCa12-IR


title: SkCa12-Mock


title: SkCa11-Mock


title: SkCa10-Mock


title: SkCa11-IR


title: SkCa9-Mock


title: SkCa8-Mock


title: SkCa9-IR


title: SkCa10-UV


title: SkCa11-UV


title: SkCa8-UV


title: SkCa10-IR


title: SkCa9-UV


title: SkCa8-IR


title: SkCa7-UV


title: SkCa5-IR


title: SkCa7-IR


title: SkCa4-UV


title: SkCa5-UV


title: SkCa5-Mock


title: SkCa6-IR


title: SkCa4-Mock


title: SkCa7-Mock


title: SkCa6-UV


title: SkCa6-Mock


title: SkCa3-UV


title: SkCa4-IR


title: SkCa3-Mock


title: SkCa2-UV


title: SkCa1-UV


title: SkCa2-IR


title: SkCa1-Mock


title: SkCa1-IR


title: NoCa14-UV


title: NoCa15-Mock